1. Home
  2. SLXN vs KZIA Comparison

SLXN vs KZIA Comparison

Compare SLXN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • KZIA
  • Stock Information
  • Founded
  • SLXN 2008
  • KZIA 1994
  • Country
  • SLXN Israel
  • KZIA Australia
  • Employees
  • SLXN N/A
  • KZIA 7
  • Industry
  • SLXN
  • KZIA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLXN
  • KZIA Health Care
  • Exchange
  • SLXN NYSE
  • KZIA Nasdaq
  • Market Cap
  • SLXN 5.0M
  • KZIA 6.0M
  • IPO Year
  • SLXN N/A
  • KZIA 1999
  • Fundamental
  • Price
  • SLXN $1.36
  • KZIA $1.08
  • Analyst Decision
  • SLXN Strong Buy
  • KZIA Strong Buy
  • Analyst Count
  • SLXN 1
  • KZIA 2
  • Target Price
  • SLXN $9.00
  • KZIA $11.50
  • AVG Volume (30 Days)
  • SLXN 32.1M
  • KZIA 5.5M
  • Earning Date
  • SLXN 02-21-2025
  • KZIA 03-26-2025
  • Dividend Yield
  • SLXN N/A
  • KZIA N/A
  • EPS Growth
  • SLXN N/A
  • KZIA N/A
  • EPS
  • SLXN N/A
  • KZIA N/A
  • Revenue
  • SLXN N/A
  • KZIA $1,655,324.00
  • Revenue This Year
  • SLXN N/A
  • KZIA $806.89
  • Revenue Next Year
  • SLXN N/A
  • KZIA N/A
  • P/E Ratio
  • SLXN N/A
  • KZIA N/A
  • Revenue Growth
  • SLXN N/A
  • KZIA 248000.00
  • 52 Week Low
  • SLXN $0.21
  • KZIA $1.15
  • 52 Week High
  • SLXN $13.56
  • KZIA $15.80
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • KZIA 32.04
  • Support Level
  • SLXN N/A
  • KZIA $1.31
  • Resistance Level
  • SLXN N/A
  • KZIA $1.60
  • Average True Range (ATR)
  • SLXN 0.00
  • KZIA 0.26
  • MACD
  • SLXN 0.00
  • KZIA 0.05
  • Stochastic Oscillator
  • SLXN 0.00
  • KZIA 0.64

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Share on Social Networks: